Recent insights into platinum drug resistance in cancer

Drug Resistance Updates

Volumn 1, Issue 4, 1998, Pages 243-254

  Johnson, Steven W ^a   Ferry, Katherine V ^a   Hamilton, Thomas C ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0000274976     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1368-7646(98)80005-8     Document Type: Review

References (144)

1. O'Dwyer P.J., Johnson S.W., and Hamilton T.C. Cisplatin and its analogues. In: DeVita Jr. V.J. (Ed). Principles and Practice of Oncology (1997), J.B. Lippincott Co., Philadelphia 418-432
2. Roberts J.J., and Thomson A.J. The mechanism of action of antitumor platinum compounds Prog. Nucleic Acids Res 22 (1979) 71-121
3. Shea T.C., Flaherty M., Elias A., et al. A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. J Clin Oncol 7 (1989) 651-661
4. Alberts D.S., Green S., Hannigan E.V., et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol 10 (1992) 683-685
5. Rixe O., Ortuzar W., Alvarez M., et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's anticancer drug screen panel. Biochem Pharmacol 52 (1996) 1855-1865
6. Schilder R.J., LaCreta F.P., Perez R.P., et al. Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule. Cancer Res 54 (1994) 709-717
7. Chollet P., Bensmaine M.A., Brienza S., et al. Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Annals Oncol 7 (1996) 1065-1070
8. Machover D., Diaz-Rubio E., de Gramount A., et al. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Annals Oncol 7 (1996) 95-98
9. Harstrick A., Bokemeyer C., Scharnofkse M., et al. Preclinical activity of a new platinum analogue, lobaplatin, in cisplatin-sensitive and -resistant human testicular, ovarian, and gastric carcinoma cell lines. Cancer Chemother. Pharmacol 33 (1993) 43-47
10. Kavanagh J.J., Edwards C.L., Freedman R.S., et al. A trial of lobaplatin (D-19466) in platinum-resistant ovarian cancer. Gynecol. Oncol 58 (1995) 106-109
11. Gietema J.A., Veldhuis G.-J., Guchelaar H.-J., et al. Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer. Br J Cancer 71 (1995) 1302-1307
12. Degardin M., Armand J.P., Chevallier B., et al. A clinical screening cooperative group phase II evaluation of lobaplatin (ASTA D-19466) in advanced head and neck cancer. Invest New Drugs 13 (1995) 253-255
13. Khokhar A.R., Al-Baker S., Shamsuddin S., and Siddik S. Chemical and biological studies on a series of novel (trans-(1R,2R)-, trans-(1S,2S)-, and cis-1,2-diaminocyclohexane)platinum (IV) carboxylate complexes. J. Med Chem 40 (1997) 112-116
14. Shamsuddin S., Takahashi I., Siddik Z.H., and Khokhar A.R. Synthesis, characterization, and antitumor activity of a series of novel cisplatin analogs with cis-1,4-diaminocyclohexane as nonleaving amine group. J Inorg Biochem 61 (1996) 291-301
15. Harrap K.R. Initiatives with platinum- and quinazoline-based antitumor molecules - Fourteenth Bruce F. Cain memorial award lecture. Cancer Res 55 (1995) 2761-2768
16. Holford J., Sharp S.Y., Murrer B.A., et al. In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473. Br J Cancer 77 (1998) 366-373
17. Farrell N. Structurally novel platinum antitumor compounds. In: Howell S.B. (Ed). Platinum and other metal coordination compounds in cancer chemotherapy (1991), Plenum Press, New York 81-91
18. Zaludova R., Zakovaska A., Kasparkova J., et al. DNA interactions of bifunctional dinuclear platinum (II) antitumor agents. Eur J Biochem 246 (1997) 508-517
19. Eastman A. The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes. Pharmacol. Ther 34 (1987) 155-166
20. Plooy A., Fichtinger-Scepman A., Schutte H.H., et al. The quantitative detection of various Pt-DNA-adducts in Chinese hamster ovary cells treated with cisplatin: application of immunochemical techniques. Carcinogenesis 6 (1985) 561-566
21. Fichtinger-Schepman A.M., van derVeer J.L., den Hartog J.H.J., et al. Adducts of the antitumor drug cis-diamminedichloroplatinum (II) with DNA: formation, identification and quantitation. Biochemistry 24 (1985) 707-713
22. Blommaert F.A., van Kijk-Knijnenburg H.C.M., Dijt F.J., et al. Formation of DNA adducts by the anticancer drug carboplatin: different nucleotide sequence preferences in vitro and in cells. Biochemistry 34 (1995) 8474-8480
23. Sherman S.E., and Lippard S.J. Structural aspects of platinum anticancer drug interactions with DNA. Chem Rev 87 (1987) 1153-1181
24. Szymkowski D.E., Yarema K., Essigmann J.M., et al. An intrastrand d(GpG) platinum crosslink in duplex M13 DNA is refractory to repair by human cell extracts. Proc Natl Acad Sci USA 89 (1992) 10772-10776
25. Knox R.J., Friedlos F., Lydall D.A., and Roberts J.J. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cisdiamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res 46 (1986) 1972-1979
26. Saris C.P., van deVaart P.J.M., Rietbroek R.C., and Blommaert F.A. In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured cells. Carcinogenesis 17 (1996) 2763-2769
27. Eastman A. Mechanisms of resistance to cisplatin. Cancer Treat Res 57 (1991) 233-249
28. Andrews P.A., and Howell S.B. Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells 2 (1990) 35-43
29. Perez R.P., Hamilton T.C., and Ozols R.F. Resistance to alkylatin agents and cisplatin: insights from ovarian carcinoma model systems. Pharmacol Ther 48 (1990) 19-27
30. Godwin A.K., Meister A., O'Dwyer P.J., et al. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase in glutathione synthesis. Proc. Natl Acad Sci USA 89 (1992) 3070-3074
31. Johnson S.W., Perez R.P., Godwin A.K., et al. Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines. Biochem Pharmacol 47 (1994) 689-697
32. Johnson S.W., Swiggard P.A., Handel L.M., et al. Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells. Cancer Res 54 (1994) 5911-5916
33. Johnson S., Laub P.B., Beesley J.S., Ozols R.F., and Hamilton T.C. Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines. Cancer Res 57 (1997) 850-856
34. Gately D.P., and Howell S.B. Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer 67 (1993) 1171-1175
35. Gale G.R., Morris C.R., Atkins L.M., and Smith A.B. Binding of an antitumor platinum compound to cells as influenced by physical factors and pharmacologically active agents. Cancer Res 33 (1973) 813-818
36. Mann S.C., Andrews P.A., and Howell S.B. Short-term cisdiamminedichloroplatinum (II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Chemother Pharmacol 25 (1990) 236-240
37. Andrews P.A., Mann S.C., Huynh H.H., and Albright K.D. Role of the Na+, K(+)-adenosine triphosphatase in the accumulation of cisdiamminedichloroplatinum(II) in human ovarian carcinoma cells. Cancer Res 151 (1991) 3677-3681
38. Andrews P.A., and Albright K.D. Role of membrane ion transport in cisplatin accumulation. In: Howell S.B. (Ed). Platinum and other metal coordination compounds in cancer chemotherapy (1991), Plenum Press, New York 151-159
39. Mann S.C., Andrews P.A., and Howell S.B. Modulation of cisdiamminedichloroplatinum(II) accumulation and sensitivity by forskolin and 3-isobutyl-1-methylxanthine in sensitive and resistant human ovarian carcinoma cells. Int J Cancer 46 (1991) 866-872
40. Shen D.-W., Pastan I., and Gottesman M.M. Cross-resistance to methotrexate and metals in human cisplatin-resistant cell lines results from a pleiotropic defect in accumulation of these compounds associated with reduced plasma membrane binding proteins. Cancer Res 58 (1998) 268-275
41. Morikage T., Bungo M., Inomata M., et al. Reversal of cisplatin resistance with amphotericin B in a non-small cell lung cancer cell line. Jpn J Cancer Res 82 (1991) 747-751
42. Morikage T., Ohmori T., Nishio K., et al. Modulation of cisplatin sensitivity and accumulation by amphotericin B in cisplatin-resistant human lung cancer cell lines. Cancer Res 53 (1993) 3302-3307
43. Kikuchi Y., Iwano I., Miyauchi M., et al. Restorative effects of calmodulin antagonists on reduced cisplatin uptake by cisplatin-resistant human ovarian carcinoma cells. Gynecol Oncol 39 (1990) 199-203
44. Kelland L.R., Mistry P., Abel G., et al. Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/ammine platinum(IV) dicarboxylates. Cancer Res 52 (1992) 3857-3864
45. Borst P., Kool M., and Evers R. Do cMOAT (MRP2), other MRP homologues, and LRP play a role in MDR?. Semin. Cancer Biol 8 (1997) 205-213
46. Taniguchi K., Wada M., Kohno K., et al. A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res 56 (1996) 4124-4129
47. Koike K., Kawabe T., Tanaka T., et al. A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells. Cancer Res 57 (1997) 5475-5479
48. Kool M., de Haas M., Scheffer G.L., et al. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRPI), in human cancer cell lines. Cancer Res 57 (1997) 3537-3547
49. Hosking L.K., Whelan R.D.H., Shellard S.A., et al. An evaluation of the role of glutathione and its associated enzymes in the expression of differential sensitivities to antitumor agents shown by a range of human tumour cell lines. Biochem Pharmacol 40 (1990) 1833-1842
50. Mistry P., Kelland L.R., Abel G., Sidhar S., and Harrap K.R. The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. Br J Cancer 64 (1991) 215-220
51. Britten R.A., Green J.A., Broughton C., et al. The relationship between nuclear glutathione levels and resistance to melphalan in human ovarian tumour cells. Biochem Pharmacol 41 (1991) 647-649
52. Hamilton T.C., Winker M.A., Louie K.G., et al. Augmentation of adriamycin, melphalan and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian cancer cell lines by buthionine sulfoximine mediated glutathione depletion. Biochem Pharmacol 34 (1985) 2583-2586
53. Smith E., and Brock A.P. An in vitro study comparing the cytotoxicity of three platinum complexes with regard to the effect of thiol depletion. Br J Cancer 57 (1988) 548-552
54. Dedon P.C., and Borch R.F. Characterization of the reactions of platinum antitumor agents with biologic and nonbiologic sulfur-containing nucleophiles. Biochem Pharmacol 36 (1987) 1955-1964
55. Ishikawa T., and Ali-Osman F. Glutathione-associated cisdiamminedichloroplatinum (II) metabolism and ATP-dependent efflux from leukemia cells. J Biol Chem 268 (1993) 20116-20125
56. Mistry P., Loh S.Y., Kelland L.R., and Harrap K.R. Effect of buthionine sulfoximine on PtII and PtIV drug accumulation and the formation of glutathione conjugates in human ovarian carcinoma cell lines. Int J Cancer 55 (1993) 848-856
57. Eastman A. Cross-linking of glutathione to DNA by cancer chemotherapeutic platinum coordination complexes. Chem Biol Interact 61 (1987) 241-248
58. Miyazaki M., Kohno K., Saburi Y., et al. Drug resistance to cisdiamminedichloroplatinum (II) in Chinese hamster ovary cell lines by transfection with glutathione S-transferase gene. Biochem Biophys Res Comm 166 (1990) 1358-1364
59. Nakagawa K., Saijo N., Tsuchida S., et al. Glutathione S-transferase π as a determinant of drug resistance in transfectant cell lines. J Biol Chem 265 (1990) 4296-4301
60. Hrubisko M., McGown A.T., and Fox B.W. The role of metallothionein, glutathione, glutathione S-transferases and DNA repair in resistance to platinum drugs in a series of L1210 cell lines made resistant to anticancer platinum agents. Biochem Pharmacol 45 (1993) 253-256
61. Pattanaik A., Bachowski G., Laib J., et al. Properties of the reaction of cis-dichlorodiammineplatinum(II) with metallothionein. J Biol Chem 267 (1992) 16121-16128
62. Kelley S.L., Basu A., Teicher B.A., et al. Overexpression of metallothionein confers resistance to anticancer drugs. Science 241 (1988) 1813-1815
63. Kondo Y., Woo E.S., Michalska A.E., et al. Metallothionein null cells have increased sensitivity to anticancer drugs. Cancer Res 55 (1995) 2021-2023
64. Kojima M., Kikkawa F., Oguchi H., et al. Sensitisation of human ovarian carcinoma cells to cis-diamminedichloroplatinum (II) by amphotericin B in vitro and in vivo. Eur J Cancer 30A (1994) 773-778
65. Lindahl T., Karran P., and Wood R.D. DNA excision repair pathways. Curr Opin Genet & Dev 7 (1997) 158-169
66. Wood R.D. Nucleotide Excision Repair in Mammalian Cells. J Biol Chem 272 (1997) 23465-23468
67. Moggs J.G., Yarema K.J., Essigmann J.M., and Wood R.D. Analysis of Incision Sites Produced by Human Cell Extracts and Purified Proteins during Nucleotide Excision Repair of a 1,3-Intrastrand d(GpTpG)-Cisplatin Adduct. J Biol Chem 271 (1996) 7177-7186
68. Cole R.S. Repair of DNA containing interstrand crosslinks in Escherichia coli: sequential excision and recombination. Proc Natl Acad Sci USA 70 (1973) 1064-1068
69. Thompson L.H. Evidence that mammalian cells possess homologous recombinational repair pathways. Mutat Res 363 (1996) 77-88
70. Prakash S., Sung P., and Prakash L. DNA repair genes and proteins of Saccharomyces cerevisiae. Ann Rev Genet 263 (1993) 12228-12234
71. Sargent R.G., Rolig R.L., Kilburn A.E., et al. Recombination-dependent deletion formation in mammalian cells deficient in the nucleotide excision repair gene ERCCI. Proc Natl Acad Sci USA 94 (1997) 13122-13127
72. Lehmann A.R. Nucleotide excision repair and the link with transcription. Trends Biochem Sci 20 (1995) 402-405
73. Tantin D., Kansal A., and Carey M. Recruitment of the Putative Transcription-Repair Coupling Factor CSB/ERCC6 to RNA Polymerase II Elongation Complexes. Mol & Cell Biol 17 (1997) 6803-6814
74. Koberle B., Grimaldi K.A., Sunters A., et al. DNA Repair Capacity and Cisplatin Sensitivity of Human Testis Tumour Cells. Int J Cancer 70 (1997) 551-555
75. Zeng-Rong N., Paterson J., Alpert L., et al. Elevated DNA Repair Capacity Is Associated with Intrinsic Resistance of Lung Cancer to Chemotherapy. Cancer Res 55 (1995) 4760-4764
76. Johnson S.W., Swiggard P.A., Handel L.M., et al. Relationship between platinum-DNA adduct formation, removal, and cytotoxicity in cisplatin sensitive and resistant human ovarian cancer cells. Cancer Res 54 (1994) 5911-5916
77. Yen L., Woo A., Christopoulopoulos G., et al. Enhanced host cell reactivation capacity and expression of DNA repair genes in human breast cancer cells resistant to bi-functional alkylating agents. Mutat. Res 337 (1995) 179-189
78. Ali-Osman F., Berger M.S., Rairkar A., and Stein D.E. Enhanced Repair of a Cisplatin-Damaged Reporter Chloramphenicol-O-Acetyltransferase Gene and Altered Activities of DNA Polymerases α and β, and DNA Ligase in Cells of a Human Malignant Glioma Following In Vivo Cisplatin Therapy. J Cell Biochem 54 (1994) 11-19
79. Eastman A., and Schulte N. Enhanced DNA Repair as a Mechanism of Resistance to cis Diamminedichloroplatinum(II). Biochemistry 27 (1988) 4730-4734
80. Zhen W., Link C.J., O'Connor P.M., et al. Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines. Mol Cell Biol 12 (1992) 3689-3698
81. Chaney S.G., and Sancar A. DNA Repair: Enzymatic Mechanisms and Relevance to Drug Response. J Natl Cancer Inst 88 (1996) 1346-1360
82. Dabholkar M., Vionnet J., Bostick-Bruton F., Yu J.J., and Reed E. Messenger RNA levels of XPAC and ERCCI in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 94 (1994) 703-708
83. Cleaver J.E., Charles W.C., McDowell M.L., et al. Overexpression of the XPA Repair Gene Increases Resistance to Ultraviolet Radiation in Human Cells by Selective Repair of DNA Damage. Cancer Res 55 (1995) 6152-6160
84. Bramson J., and Panasci L.C. Effect of ERCC-I Overexpression on Sensitivity of Chinese Hamster Ovary Cells to DNA Damaging Agents. Cancer Res 53 (1993) 3237-3240
85. Chu G., and Chang E. Cisplatin-resistant cells express increased levels of a factor that recognizes damaged DNA. Proc Natl Acad Sci USA 87 (1990) 3324-3328
86. Hoffmann J.S., Pillaire M.J., Maga G., et al. DNA polymerase beta bypasses in vitro a single d(GpG)-cisplatin adduct placed on codon 13 of the HRAS gene. Proc Natl Acad. Sci USA 92 (1995) 5356-5360
87. Hughes E.N., Engelsberg B.N., and Billings P.C. Purification of Nuclear Proteins That Bind to Cisplatin-damaged DNA. J Biol Chem 267 (1992) 13520-13527
88. Treiber D.K., Zhai X., Jantzen H.-M., and Essigmann J.M. Cisplatin-DNA adducts are molecular decoys for the ribosomal RNA transcription factor hUBF (human upstream binding factor). Proc Natl Acad Sci 91 (1994) 5672-5676
89. Bruhn S.L., Pil P.M., Essigmann J.M., et al. Isolation and characterization of human cDNA clones encoding a high mobility group box protein that recognizes structural distortions to DNA caused by binding of the anticancer agent cisplatin. Proc Natl Acad Sci USA 89 (1989) 2307-2311
90. Brown S.J., Kellett P.J., and Lippard S.J. Ixrl, a Yeast Protein That Binds to Platinated DNA and Confers Sensitivity to Cisplatin. Science 261 (1993) 603-605
91. Huang J.-C., Zamble D.B., Reardon J.T., et al. HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. Proc Natl Acad Sci USA 91 (1994) 10394-10398
92. McA'Nulty M., and Lippard S.J. The HMG-domain protein Ixrl blocks excision repair of cisplatin-DNA adducts in yeast. Mutat Res 362 (1996) 75-86
93. Yaneva J., Leuba S.H., van Holde K., and Zlatanova J. The major chromatin protein histone HI binds preferentially to cis-platinum-damaged DNA. Proc Natl Acad Sci USA 94 (1997) 13448-13451
94. Vichi P., Coin F., Renaud J.P., et al. Cisplatin- and UV-Damaged DNA Lure the Basal Transcription Factor TFIID/TBP. EMBO J 16 (1997) 7444-7456
95. Katz E.J., Andrews P.A., and Howell S.B. The Effect of DNA Polymerase Inhibitors on the Cytotoxicity of Cisplatin in Human Ovarian Carcinoma. Cells Cancer Comm 2 (1990) 159-164
96. Dempke W.C.M., Shellard S.A., Fichtinger-Schepman A., and Hill B.T. Lack of significant modulation of the formation and removal of platinum-DNA adducts by aphidicolin glycinate in two logarithmically-growing ovarian tumour cell lines in vitro. Carcinogenesis 12 (1991) 525-528
97. O'Dwyer P.J., Moyer J.D., Suffness M., et al. Antitumor Activity and Biochemical Effects of Aphidicolin Glycinate (NSC 303812) Alone and in Combination with Cisplatin in Vivo. Cancer Res 54 (1994) 724-729
98. Albain K.S., Swinnen L.J., Erickson L.C., et al. Cytotoxic Synergy of Cisplatin with Concurrent Hydroxyurea and Cytarabine: Summary of an In Vitro Model and Initial Clinical Pilot Experience. Semin. Oncol. 19 (1992) 102-109
99. Alaoui-Jamali M., Loubaba B.-B., Robyn S., et al. Effect of DNA-repair-enzyme modulators on cytotoxicity of L-phenylalanine mustard and cis-diamminedichloroplatinum (II) in mammary carcinoma cells resistant to alkylating agents. Cancer Chemother Pharmacol 34 (1994) 153-158
100. Peters G.J., Bergman A.M., Ruiz van Haperen V.W., et al. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 22 (1995) 72-79
101. Li L., Keatin M.J., Plunkett W., and Yang L.-Y. Fludarabine-Mediated Repair Inhibition of Cisplatin-Induced DNA Lesions in Human Chronic Myelogenous Leukemia-Blast Crisis K562 Cells: Induction of Synergistic Cytotoxicity Independent of Reversal of Apoptosis Resistance. Mol Pharm 52 (1997) 798-806
102. abstract. Nagourney R.A., Su Y.Z., Link J., et al. Gemcitabine synergy with cisplatin. Clinical and laboratory correlates. Proc Am Assoc Cancer Res 39 (1998) 310
103. Aebi S., Kurdi-Haidar B., Gordon R., et al. Loss of DNA Mismatch Repair in Acquired Resistance to Cisplatin. Cancer Res 56 (1996) 3087-3090
104. Boyer J.C., Umar A., Risinger J.I., et al. Microsatelite Instability, Mismatch Repair Deficiency, and Genetic Defects in Human Cancer Cell Lines. Cancer Res 55 (1995) 6063-6070
105. Koi M., Umar A., Chauhan D.P., et al. Human Chromosome 3 Corrects Mismatch Repair Deficiency and Microsatellite Instability and Reduces N-Methyl-N'-nitro-N-nitrosoguanidine Tolerance in Colon Tumor Cells with Homozygous Cells with Homozygous hMLHI Mutation. Cancer Res 54 (1994) 4308-4312
106. Fink D., Nebel S., Aebi S., et al. The Role of DNA Mismatch Repair in Platinum Drug Resistance. Cancer Res 56 (1996) 4881-4886
107. Umar A., Boyer J.C., and Kunkel T.A. DNA Loop Repair by Human Cell Extracts. Science 266 (1994) 814-816
108. Fink D., Zheng H., Nebel S., et al. In Vitro and In Vivo Resistance to Cisplatin in Cells That Have Lost DNA Mismatch Repair. Cancer Res 57 (1997) 1841-1845
109. Mello J.A., Acharya S., Fishel R., and Essigmann J.M. The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin. Chem. & Biol 3 (1996) 579-589
110. Duckett D.R., Drummond J.T., Murchie A.J., et al. Human MutSα recognizes damaged DNA base pairs containing 06-methylguanine, O4-methylthymine, or the cisplatin-d(GpG)adduct. Proc Natl Acad Sci USA 93 (1996) 6443-6447
111. Karran P., and Bignami M. DNA damage tolerance, mismatch repair and genome instability. BioEssays 16 (1994) 833-839
112. Mamenta E.L., Poma E.E., Kaufmann W.K., et al. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res 54 (1994) 3500-3505
113. Kaufmann W.K. Pathways of human cell post-replication repair. Carcinogenesis 10 (1989) 1-10
114. Eastman A. Activation of programmed cell death by anticancer agents: Cisplatin as a model system. Cancer Cells 2 (1990) 275-280
115. Henkels K.M., and Turchi J.J. Induction of apoptosis in cisplatin-sensitive and -resistant human ovarian cancer cell lines. Cancer Res 57 (1997) 4488-4492
116. Sorrenson C.M., and Eastman A. Mechanism of cis-diamminedichloroplatinum (II)-induced cytotoxicity: role of G2 arrest and DNA double-strand breaks. Cancer Res 48 (1988) 4484-4488
117. Vaisman A., Varchenko M., Said I., and Chaney S.G. Cell cycle changes associated with formation of Pt-DNA adducts in human ovarian carcinoma cells with different cisplatin sensitivity. Cytometry 27 (1997) 54-64
118. Demarcq C., Bunch R.T., Creswell D., and Eastman A. The role of cell cycle progresson in cisplatin-induced apoptosis in Chinese hamster ovary cells. Cell Growth and Differentiation 5 (1994) 983-993
119. El-Deiry W.S., Tokino T., Velculescu V.E., et al. WAF1, a potential mediator of p53 tumor suppression. Cell 75 (1993) 817-825
120. Fornace Jr. A.J., Nebert D.W., Hollander M.C., et al. Mammalian genes coordinately regulated by growth arrest signals and DNA-damaging agents. Mol Cell Biol 9 (1989) 4196-4203
121. Delmastro D.A., Li J., Vaisman A., et al. DNA damage inducible-gene expression following platinum treatment in human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 39 (1997) 245-253
122. McDonald III E.R., Wu G.S., Waldman T., and El-Deiry W.S. Repair Defect in p21 WAF1/CIP1 -/- human cancer cells. Cancer Res 56 (1996) 2250-2255
123. Chen I.T., Smith M.L., O'Connor P.M., and Fornace Jr. A.J. Direct interaction of Gadd45 with PCNA and evidence for competitive interaction of Gadd45 and p21 Waf1/Cip1 with PCNA. Oncogene 11 (1995) 1931-1937
124. Lowe S.W., Ruley H.E., Jacks T., and Housman D.E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74 (1993) 957-967
125. Fan S., Smith M.L., Rivet II D.J., et al. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 55 (1995) 1649-1654
126. Eliopoulos A.G., Kerr D.J., Herod J., et al. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene 11 (1995) 1217-1228
127. Blagosklonny M.V., and Eldeiry W.S. Acute overexpression of WT p53 facilitates anticancer drug-induced death of cancer and normal cells. Int J Cancer 75 (1998) 933-940
128. Bunch R.T., and Eastman A. 7-Hydroxystaurosporine (UCN-01) causes redistribution of proliferating cell nuclear antigen and abrogates cisplatin-induced S-phase arrest in Chinese hamster ovary cells. Cell Growth Differ 8 (1997) 779-788
129. Schlegel R., and Pardee A.B. Mechanism by which caffeine potentiates lethality of nitrogen mustard. Proc Natl Acad. Sci USA 79 (1982) 2942-2946
130. Schlegel R., Belinsky G.S., and Harris M.O. Premature mitosis induced in mammalian cells by the protein kinase inhibitors 2-aminopurine and 6-dimethylaminopurine. Cell Growth Differ 1 (1990) 171-178
131. Bernhard E.J., Maity A., Muschel R.J., and McKenna W.G. Increased expression of cyclin B1 mRNA coincides with diminished G2-phase arrest in irradiated HeLa cells treated with staurosporine or caffeine. Radiat Res 140 (1994) 393-400
132. Wang Q., Fan S., Eastman A., et al. UCN-01: A potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J Natl. Cancer Inst. 88 (1996) 956-965
133. McClay E.F., Albright K.D., Jones J.A., et al. Modulation of cisplatin resistance in human malignant melanoma cells. Cancer Res 52 (1992) 6790-6796
134. Kroning R., Jones J.A., Hom D.K., et al. Enhancement of drug sensitivity of human malignancies by epidermal growth factor. Br J Cancer 72 (1995) 615-619
135. Chang M.J., Yu W.D., Reyno L.M., et al. Potentiation by interleukin I alpha of cisplatin and carboplatin antitumor activity: schedule-dependent and pharmacokinetic effects in the RIF-1 tumor model. Cancer Res 54 (1994) 5380-5386
136. Isonishi S., Jekunen A.P., Hom D.K., et al. Modulation of cisplatin sensitivity and growth rate of an ovarian carcinoma cell line by bombesin and tumor necrosis factor-alpha. J Clin Invest 90 (1992) 1436-1442
137. Fan J., Banerjee D., Stambrook P.J., and Bertino J.R. Modulation of cytotoxicity of chemotherapeutic drugs by activated H-ras. Biochem Pharmacol 53 (1997) 1203-1209
138. Isonishi S., Hom D.K., Thiebaut F.B., et al. Expression of the c-Ha-ras oncogene in mouse NIH 3T3 cells induces resistance to cisplatin. Cancer Res 51 (1991) 5903-5909
139. Chapman R.S., Whetton A.D., Chresta C.M., and Dive C. Characterization of drug resistance mediated via the suppression of apoptosis by Abelson protein tyrosine kinase. Mol Pharmacol 48 (1995) 334-343
140. Benz C.C., Scott G.K., Sarup J.C., et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 24 (1993) 85-95
141. Miyashita T., and Reed J.C. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cells line. Blood 81 (1993) 151-157
142. l can confer a multidrug resistance phenotype. Blood 86 (1995) 1903-1910
143. Zou H., Henzel W.J., Liu X., et al. Apaf-1, a human protein homolgous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell 90 (1997) 405-413
144. Hirsch T., Marchetti P., Susin S.A., et al. The apoptosis-necrosis paradox. Apoptogenic proteases activated after mitochondrial permeability transition determine the mode of cell death. Oncogene 15 (1997) 1573-1581